{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:01:17Z","timestamp":1784170877819,"version":"3.55.0"},"reference-count":265,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jconrel.2022.06.034","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T11:49:46Z","timestamp":1656676186000},"page":"970-1003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Sustained drug delivery strategies for treatment of common substance use disorders: Promises and challenges"],"prefix":"10.1016","volume":"348","author":[{"given":"Akeemat O.","family":"Tijani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jivesh","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorcas","family":"Frempong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Verana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagroop","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Joga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan D.","family":"Sabanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashana","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.06.034_bb0010","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2013.12060782","article-title":"DSM-5 criteria for substance use disorders: recommendations and rationale","volume":"170","author":"Hasin","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0025","author":"Key Substance Use and Mental Health Indicators in the United States: Results from the"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0030","unstructured":"Overdose Death Rates. National Institute on Drug Abuse (NIDA), https:\/\/nida.nih.gov\/drug-topics\/trends-statistics\/overdose-death-rates (accessed May 30, 2022)."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0040","author":"Addiction and Health"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0050","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/08897077.2020.1784363","article-title":"Substance abuse COVID-19 and persons with substance use disorders: Inequities and mitigation strategies COVID-19 and persons with substance use disorders: Inequities and mitigation strategies","volume":"41","author":"Melamed","year":"2020","journal-title":"Subst. Abus."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113096","article-title":"The COVID-19 pandemic and its impact on substance use: Implications for prevention and treatment","volume":"289","author":"Ornell","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108766","article-title":"Covid-19 interface with drug misuse and substance use disorders","volume":"198","author":"Cisneros","year":"2021","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0065","article-title":"Substance use disorder and telemedicine: opportunity and concern for the future","author":"Shakir","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0070","author":"Treatment Approaches for Drug Addiction DrugFacts"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0075","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/19371918.2013.759031","article-title":"Medications for substance use disorders","volume":"28","author":"Douaihy","year":"2013","journal-title":"Soc. Work Public Health."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0080","author":"Substance Abuse and Mental Health Services Administration (US), Office of the Surgeon General (US). Facing addiction in America: The surgeon general's report on alcohol, drugs, and health [Internet]. US department of health and human services, Washington (DC)"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0085","article-title":"Detoxification of drug and substance abuse","author":"Das","year":"2020","journal-title":"Med. Toxicol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/TCRM.S23184","article-title":"Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility","volume":"8","author":"Witkiewitz","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0100","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2147\/DDDT.S72543","article-title":"Advances in the delivery of buprenorphine for opioid dependence","volume":"11","author":"R. RN, G. VV","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0105","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2174\/138161211796150846","article-title":"Pharmacological treatment of cannabis dependence","volume":"17","author":"Weinstein","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0110","doi-asserted-by":"crossref","first-page":"E537","DOI":"10.1503\/cmaj.160357","article-title":"Flumazenil in benzodiazepine overdose","volume":"188","author":"An","year":"2016","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial","volume":"116","author":"Levin","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s13346-019-00685-4","article-title":"The pharmacokinetics of 3-fluoroamphetamine following delivery using clinically relevant routes of administration","volume":"10","author":"Jiang","year":"2020","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120739","article-title":"Microneedle-mediated transdermal delivery of naloxone hydrochloride for treatment of opioid overdose","volume":"604","author":"Puri","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0140","first-page":"29","article-title":"Buprenorphine: a (Relatively) new treatment for opioid dependence","volume":"2","author":"Welsh","year":"2005","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0145","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s11095-007-9470-6","article-title":"BupredermTM, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies","volume":"25","author":"Park","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0155","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1016\/j.xphs.2021.05.015","article-title":"Transdermal route: a viable option for systemic delivery of antidepressants","volume":"110","author":"Tijani","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4155\/tde-2020-0096","article-title":"Characterization of microneedles and microchannels for enhanced transdermal drug delivery","volume":"12","author":"Puri","year":"2021","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jconrel.2021.05.005","article-title":"Delivering therapeutic cannabinoids via skin: Current state and future perspectives","volume":"334","author":"Tijani","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijpharm.2015.11.029","article-title":"Development and characterisation of sustained release solid dispersion oral tablets containing the poorly water-soluble drug disulfiram","volume":"497","author":"Shergill","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/B978-0-12-820757-4.00001-6","article-title":"Surface engineering of nanoparticles for imparting multifunctionality","author":"Choudhury","year":"2022","journal-title":"Nanopart. Therap."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006140.pub2","article-title":"Sustained-release naltrexone for opioid dependence","author":"Lobmaier","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0185","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/jps.2600731214","article-title":"Sustained-release characteristics of a new implantable formulation of disulfiram","volume":"73","author":"Phillips","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0195","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0200","article-title":"Nicotine loaded dissolving microneedles for nicotine replacement therapy","volume":"61","author":"Panda","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cej.2013.12.106","article-title":"molecularly imprinted polymers as nicotine transdermal delivery systems","volume":"248","author":"Ruela","year":"2014","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0210","doi-asserted-by":"crossref","first-page":"11698","DOI":"10.1073\/pnas.1004714107","article-title":"Programmable transdermal drug delivery of nicotine using carbon nanotube membranes","volume":"107","author":"Wu","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0215","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jnr.24627","article-title":"Slow-sustained delivery of naloxone reduces typical naloxone-induced precipitated opioid withdrawal effects in male morphine-dependent mice","volume":"100","author":"Lewter","year":"2022","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0220","series-title":"Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence","first-page":"389","volume":"1","author":"Volpicelli","year":"2006"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0225","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/03639040801929075","article-title":"Synthesis and evaluation of novel polyester-ibuprofen conjugates for modified drug release","volume":"34","author":"Thompson","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0230","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.msec.2015.12.004","article-title":"Marbofloxacin-encapsulated microparticles provide sustained drug release for treatment of veterinary diseases","volume":"60","author":"Lee","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11120671","article-title":"Poloxamer hydrogels for biomedical applications","volume":"11","author":"Russo","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0240","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/jps.21463","article-title":"Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: A prodrug strategy as an alternative approach","volume":"98","author":"Kiptoo","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0245","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1016\/j.xphs.2019.08.025","article-title":"Development of hydrogels for microneedle-assisted transdermal delivery of naloxone for opioid-induced pruritus","volume":"108","author":"Gao","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0250","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/13543784.16.8.1285","article-title":"Sustained-release naltrexone: Novel treatment for opioid dependence","volume":"16","author":"Comer","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119474","article-title":"Bioresponsive nanostructured systems for sustained naltrexone release and treatment of alcohol use disorder: Development and biological evaluation","volume":"585","author":"Santos","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0260","first-page":"351","article-title":"Preparation and in-vitro evaluation of gastroretentive bupropion hydrochloride tablets","volume":"11","author":"Fouladi","year":"2012","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0265","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1021\/acsptsci.1c00168","article-title":"Covalently loaded naloxone nanoparticles as a long-acting medical countermeasure to opioid poisoning","volume":"4","author":"Kassick","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0270","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.mcna.2016.03.011","article-title":"Pharmacotherapy for substance use disorders","volume":"100","author":"Klein","year":"2016","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0275","author":"NIMH"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0285","author":"Mental Health and Substance Use Disorders, SAMHSA"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0290","doi-asserted-by":"crossref","DOI":"10.1176\/ps.62.9.pss6209_1007","article-title":"Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment","volume":"62","author":"Wisdom","year":"2011","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0300","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"25","author":"Witkiewitz","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0305","author":"How Illicit Drug Use Affects Business and the Economy"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0315","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1037\/a0013628","article-title":"Opioids and the treatment of chronic pain: controversies, current status, and future directions","volume":"16","author":"Rosenblum","year":"2008","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0320","doi-asserted-by":"crossref","unstructured":"Opioid use disorder. Nat. Rev. Dis. Prim., 6(1) doi:https:\/\/doi.org\/10.1038\/s41572-019-0137-5.","DOI":"10.1038\/s41572-019-0137-5"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0325","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1213\/ANE.0000000000002496","article-title":"Risk factors for opioid-use disorder and overdose","volume":"125","author":"Webster","year":"2017","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0330","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/00365510701532662","article-title":"Biomarkers of alcoholism: An updated review","volume":"68","author":"Das","year":"2008","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0335","author":"Alcohol"},{"issue":"112","key":"10.1016\/j.jconrel.2022.06.034_bb0350","article-title":"Substance misuse and substance use disorders: why do they matter in healthcare?","volume":"128","author":"McLellan","year":"2017","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0355","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619875925","article-title":"Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials","volume":"13","author":"Nagano","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0365","author":"Cocaine DrugFacts"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0370","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1151\/spp05314","article-title":"The neurobiology of cocaine addiction","volume":"3","author":"Nestler","year":"2005","journal-title":"Sci. Pract. Perspect."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0375","author":"Marijuana"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0385","author":"Data and Statistics"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0400","author":"DrugFacts"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0405","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/phar.1747","article-title":"Treatment of cannabis use disorder: current science and future outlook","volume":"36","author":"Sherman","year":"2016","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0410","doi-asserted-by":"crossref","first-page":"259","DOI":"10.9740\/mhc.2020.09.259","article-title":"Lofexidine for acute opioid withdrawal: a clinical case series","volume":"10","author":"Renfro","year":"2020","journal-title":"Mental Health Clin."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0415","article-title":"Clinical efficacy and safety profile of lofexidine hydrochloride in treating opioid withdrawal symptoms: a review of literature","volume":"11","author":"Rehman","year":"2019","journal-title":"Cureus."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0425","series-title":"Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment","first-page":"821","article-title":"The synthetic analog of \u03949-tetrahydrocannabinol (THC): Nabilone. pharmacology and clinical application","author":"Balter","year":"2017"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0435","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/11536100-000000000-00000","article-title":"Combination pharmacotherapy for stopping smoking: What advantages does it offer?","volume":"70","author":"Ebbert","year":"2010","journal-title":"Drugs."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0440","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bcp.12116","article-title":"Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice","volume":"77","author":"Aubin","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0445","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/FBP.0b013e32834d63ac","article-title":"Effects of monoamine releasers with varying selectivity for releasing dopamine\/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys","volume":"22","author":"Banks","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0450","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drugalcdep.2017.04.020","article-title":"A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults","volume":"177","author":"Gray","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0455","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1373\/clinchem.2010.152439","article-title":"Plasma cannabinoid pharmacokinetics following controlled oral \u0394 9-tetrahydrocannabinol and oromucosal cannabis extract administration","volume":"57","author":"Karschner","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0465","first-page":"63","article-title":"Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study","volume":"6","author":"Penetar","year":"2012","journal-title":"Subst. Abuse: Res. Treat."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0470","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.copsyc.2020.11.002","article-title":"Interventions for cannabis use disorder","volume":"38","author":"Winters","year":"2021","journal-title":"Curr. Opin. Psychol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0475","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40429-014-0011-1","article-title":"Novel pharmacologic approaches to treating cannabis use disorder","volume":"1","author":"Balter","year":"2014","journal-title":"Curr. Addict. Rep."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0490","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/j.1360-0443.2008.02345.x","article-title":"Persistence with oral naltrexone for alcohol treatment: implications for healthcare utilization","volume":"103","author":"Kranzler","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13690-021-00550-2","article-title":"Evaluating level of adherence to nicotine replacement therapy and its impact on smoking cessation: a systematic review and meta-analysis","volume":"79","author":"Mersha","year":"2021","journal-title":"Arch. Public Health."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0500","series-title":"Therapeutics and Clinical Risk Management.","first-page":"741","article-title":"Naltrexone long-acting formulation in the treatment of alcohol dependence","volume":"3","author":"Johnson","year":"2007"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0505","series-title":"NALTREXONE: A REView of Existing Sustained Drug Delivery Systems and Emerging Nano-Based Systems","author":"Goonoo","year":"2014"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0510","first-page":"592","article-title":"Association of out-of-pocket pharmacy costs with adherence to varenicline","volume":"20","author":"Suehs","year":"2014","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpainsymman.2004.07.005","article-title":"Buprenorphine: considerations for pain management","volume":"29","author":"Johnson","year":"2005","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0520","first-page":"67","article-title":"A case report of seizure induced by bupropion nasal insufflation","volume":"9","author":"Hill","year":"2007","journal-title":"Prim. Care Compan. J. Clin. Psychiatry."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0525","first-page":"1948","article-title":"In vitro\/in vivo evaluation of agar nanospheres for pulmonary delivery of bupropion HCl","volume":"23","author":"Varshosaz","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0530","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/SAR.S101700","article-title":"Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review","volume":"8","author":"Lewis","year":"2017","journal-title":"Subst. Abus. Rehabil."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0535","article-title":"Methadone at tapered doses for the management of opioid withdrawal","author":"Amato","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0540","doi-asserted-by":"crossref","DOI":"10.1038\/sj.npp.1300274","article-title":"Vivitrex, An injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats","volume":"28","author":"Bartus","year":"2003","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0545","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/ajad.12786","article-title":"Adherence to extended-release naltrexone: patient and treatment characteristics","volume":"27","author":"Chang","year":"2018","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0550","doi-asserted-by":"crossref","first-page":"e219041","DOI":"10.1001\/jamanetworkopen.2021.9041","article-title":"Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial","volume":"4","author":"Lintzeris","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0555","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000520091","article-title":"Perception of a new prolonged-release buprenorphine formulation in patients with opioid use disorder: The PREDEPO study","volume":"28","author":"Pascual","year":"2022","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0560","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.4103\/jfmpc.jfmpc_313_20","article-title":"Nicotine replacement therapy: a friend or foe","volume":"9","author":"Devi","year":"2020","journal-title":"J. Family Med. Primary Care."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0565","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1176\/appi.focus.20180043","article-title":"Novel formulations of buprenorphine for treatment of opioid use disorder","volume":"17","author":"Rosenthal","year":"2019","journal-title":"Focus (Madison)."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0570","series-title":"Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects","first-page":"293","volume":"51","author":"Costa","year":"2019"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0575","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jddst.2018.06.027","article-title":"An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation","volume":"47","author":"Kamali","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0580","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/JAN.0000000000000223","article-title":"Sublocade: the once-monthly buprenorphine injectable","volume":"29","author":"Lorman","year":"2018","journal-title":"J. Addict. Nurs."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0585","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.therap.2020.05.007","article-title":"Prolonged-release buprenorphine formulations: perspectives for clinical practice","volume":"75","author":"Chappuy","year":"2020","journal-title":"Therapies."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0590","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/clpt.1984.243","article-title":"Kinetics of a naltrexone sustained-release preparation","volume":"36","author":"Chiang","year":"1984","journal-title":"Clin. Pharmacol. Therap."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0595","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/03639045.2010.535540","article-title":"Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres","volume":"37","author":"Akala","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121275","article-title":"Comparison of lipid liquid crystal formulation and Vivitrol\u00ae for sustained release of Naltrexone: In vitro evaluation and pharmacokinetics in rats","volume":"611","author":"Kamali","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and recent progress in oral drug delivery systems for biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0610","article-title":"Oral sustained release tablets: an overview with a special emphasis on matrix tablet","volume":"5","author":"Goyal","year":"2017","journal-title":"Am. J. Adv. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0615","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s13346-018-0494-8","article-title":"R.O.W. Sustained-release amorphous solid dispersions","volume":"8","author":"Maincent","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0620","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsps.2010.11.002","article-title":"Effect of Kollidon\u00ae SR on the release of Albuterol Sulphate from matrix tablets","volume":"19","author":"Sakr","year":"2011","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0625","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/B978-0-12-813689-8.00015-X","article-title":"Oral controlled and sustained drug delivery systems: concepts, advances, preclinical, and clinical status","author":"Kaur","year":"2018","journal-title":"Drug Target. Stimuli Sens. Drug Deliv. Syst."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0635","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/jps.21119","article-title":"N-methylation and N-formylation of a secondary amine drug (varenicline) in an osmotic tablet","volume":"97","author":"Waterman","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0650","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bcp.12011","article-title":"Injectable and implantable sustained release naltrexone in the treatment of opioid addiction","volume":"77","author":"Kun\u00f8e","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2022.06.034_bb0655","first-page":"702","article-title":"Sustained release injectable formulations: its rationale","volume":"4","author":"Karode","year":"2015","journal-title":"Recent Progr. Advance."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0660","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-200241060-00002","article-title":"Pharmacokinetics of the carmustine implant","volume":"41","author":"Fleming","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0665","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/jps.2600790927","article-title":"Pharmaceutical dosage forms: Disperse systems. Volume 2. Edited by Herbert A. Lieberman, Martin M. Reiger, and Gilbert S. Banker. Marcel Dekker: New York. 1989. 26 \u00d7 18 cm. xx + 690 pp. $125.00","volume":"79","author":"Tabibi","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0670","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nbt.1504","article-title":"Transdermal drug delivery","volume":"26","author":"Prausnitz","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0675","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1515\/bmt-2019-0019","article-title":"Non-invasive drug delivery technology: development and current status of transdermal drug delivery devices, techniques and biomedical applications","volume":"65","author":"Akhtar","year":"2020","journal-title":"Biomed. Tech."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0690","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2009.05.017","article-title":"Double-layer weekly sustained release transdermal patch containing gestodene and ethinylestradiol","volume":"377","author":"Gao","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0695","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/jphi.JPHI_35_16","article-title":"Formulation and evaluation of transdermal drug delivery of topiramate","volume":"7","author":"Cherukuri","year":"2017","journal-title":"Int. J. Pharm. Invest."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0700","series-title":"Transdermal nicotine mixed natural rubber-hydroxypropylmethylcellulose film forming systems for smoking cessation: in vitro evaluations","first-page":"966","volume":"20","author":"Pichayakorn","year":"2014"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0705","article-title":"Transdermal film containing nicotine and bupropion for combined smoking cessation therapy","volume":"20","author":"Nicoli","year":"2008","journal-title":"Pharm. Technol. Eur."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0710","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-0040-1701435","article-title":"Current advances in sustained release microneedles","volume":"2","author":"Du","year":"2020","journal-title":"Pharmaceut. Fronts."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0715","article-title":"Applications of synthetically produced materials in clinical medicine","author":"Hashmi","year":"2018","journal-title":"Ref. Module Mater. Sci. Mater. Eng."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0720","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4155\/tde.10.16","article-title":"Challenges and opportunities in dermal\/transdermal delivery","volume":"1","author":"Paudel","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0725","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1517\/17425247.2012.637107","article-title":"Adhesive properties: a critical issue in transdermal patch development","volume":"9","author":"Cilurzo","year":"2012","journal-title":"Exp. Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0730","doi-asserted-by":"crossref","unstructured":"A. Y\u0131ld\u0131z-Pek\u00f6z, C. Ehrhardt, pharmaceutics Editorial Advances in Pulmonary Drug Delivery, (n.d.). doi:10.3390\/pharmaceutics12100911.","DOI":"10.3390\/pharmaceutics12100911"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0735","doi-asserted-by":"crossref","first-page":"513","DOI":"10.5731\/pdajpst.2011.00704","article-title":"Pulmonary drug delivery: novel pharmaceutical technologies breathe new life into the lungs","volume":"65","author":"Nanjwade","year":"2011","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0740","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1142\/9781860949074_0017","article-title":"Aerosols as drug carriers","author":"Labiris","year":"2006","journal-title":"Nanopart. Drug Carriers."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0745","first-page":"123","article-title":"Improved treatment of nicotine addiction and emerging pulmonary drug delivery","volume":"6","author":"Islam","year":"2012","journal-title":"Drug. Discov. Ther."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0750","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","article-title":"Nanoparticles for drug delivery to the lungs","volume":"25","author":"Sung","year":"2007","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0755","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1021\/acschemneuro.0c00141","article-title":"Novel oral nanoparticle formulation of sustained release naloxone with mild withdrawal symptoms in mice","volume":"11","author":"Madison","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0760","series-title":"Product Monograph","year":"2020"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0765","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/JCP.0000000000000862","article-title":"Pharmacokinetics of sustained-release oral dexamphetamine sulfate in cocaine and heroin-dependent patients","volume":"38","author":"Herbrink","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0770","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2007.06.007","article-title":"Blood naltrexone levels over time following naltrexone implant","volume":"32","author":"Ngo","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0775","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1360-0443.2007.01817.x","article-title":"Overcoming opioid blockade from depot naltrexone (Prodetoxon\u00ae)","volume":"102","author":"Kruptisky","year":"2007","journal-title":"Addiction."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0780","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","article-title":"Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence","volume":"69","author":"Krupitsky","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0785","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1300\/J251v07n01_05","article-title":"Persistent sensitivity to ethanol following a single dose of parenteral sustained-release disulfiram","volume":"7","author":"Phillips","year":"1987","journal-title":"Adv. Alcohol. Subst Abuse."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0790","series-title":"Open-Label Pilot Study of Injectable Naltrexone for Cannabis Dependence","first-page":"619","volume":"44","author":"Notzon","year":"2018"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0795","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10837450.2013.784334","article-title":"Naltrexone-loaded poly [La\u2013(Glc\u2013Leu)] polymeric microspheres for the treatment of alcohol dependence: in vitro characterization and in vivo biocompatibility assessment","volume":"19","author":"Pagar","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0800","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0168-3659(88)90082-X","article-title":"A one-week subdermal delivery system for l-methadone based on biodegradable microcapsules","volume":"7","author":"Cha","year":"1988","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0805","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/a-1298-4508","article-title":"Novel long-acting buprenorphine medications for opioid dependence: current update","volume":"54","author":"Soyka","year":"2021","journal-title":"Pharmacopsychiatry."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0810","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.memsci.2012.04.017","article-title":"Nicotine transdermal patches using polymeric natural rubber as the matrix controlling system: effect of polymer and plasticizer blends","volume":"411\u2013412","author":"Pichayakorn","year":"2012","journal-title":"J. Membr. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0815","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.eurpolymj.2018.01.021","article-title":"Adsorption and release of nicotine from imprinted particles synthesised by precipitation polymerisation: optimising transdermal formulations","volume":"100","author":"Ruela","year":"2018","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0820","series-title":"Acrylic Matrix Type Nicotine Transdermal Patches: In Vitro Evaluations and Batch-to-Batch Uniformity","first-page":"843","volume":"29","author":"Pongjanyakul","year":"2003"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0825","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-020-01649-5","article-title":"Transdermal delivery of the free base of 3-fluoroamphetamine: in vitro skin permeation and irritation potential","volume":"21","author":"Jiang","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0830","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jddst.2018.07.012","article-title":"Transdermal formulation of 4-benzylpiperidine for cocaine-use disorder","volume":"47","author":"Ganti","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0835","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.msec.2014.12.012","article-title":"Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study","volume":"48","author":"Esposito","year":"2015","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0840","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1001\/jama.2019.5523","article-title":"Medication-based treatment to address opioid use disorder","volume":"321","author":"Leshner","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0845","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0850","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/mabi.200600129","article-title":"Biodegradable injectable in situ depot-forming drug delivery systems","volume":"6","author":"Chitkara","year":"2006","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0855","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0860","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial","volume":"74","author":"Walsh","year":"2017","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0865","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0870","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/add.14636","article-title":"Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder","volume":"114","author":"Frost","year":"2019","journal-title":"Addiction."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0875","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0880","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cct.2015.01.005","article-title":"Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial","volume":"41","author":"Lee","year":"2015","journal-title":"Contemp. Clin. Trials."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0885","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cct.2016.05.002","article-title":"Extended-release naltrexone opioid treatment at jail reentry (XOR)","volume":"49","author":"McDonald","year":"2016","journal-title":"Contemp. Clin. Trials."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0890","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-013-0110-x","article-title":"Extended-release intramuscular naltrexone (VIVITROL\u00ae): a review of its use in the prevention of relapse to opioid dependence in detoxified patients","volume":"27","author":"Syed","year":"2013","journal-title":"CNS Drugs."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0895","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025013","article-title":"In situ forming depot as sustained-release drug delivery systems","volume":"36","author":"Kanwar","year":"2019","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0900","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/02652048.2012.742158","article-title":"An overview of preparation and evaluation sustained-release injectable microspheres","volume":"30","author":"Hu","year":"2013","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0905","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0142-9612(00)00214-3","article-title":"In vivo-in vitro study of biodegradable methadone delivery systems","volume":"22","author":"Negr\u00edn","year":"2001","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0910","first-page":"143","article-title":"Matrix type drug delivery system: a review","volume":"1","author":"Patel","year":"2011","journal-title":"J. Pharmaceut. Sci. Biosci. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0915","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archgenpsychiatry.2009.130","article-title":"Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone","volume":"66","author":"Hulse","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11094-005-0066-3","article-title":"Pharmacokinetic study of the new domestic hypodermic form of naltrexone: prodetoxon depot tablets","volume":"39","author":"Ramenskaya","year":"2005","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0925","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000092115","article-title":"Naltrexone implants \u2013 duration, tolerability and clinical usefulness","volume":"12","author":"Waal","year":"2006","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0930","first-page":"1","article-title":"Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program","volume":"2","author":"Reece","year":"2007","journal-title":"Subst. Abuse: Treat. Prevent. Policy."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0935","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/08897077.2015.1010032","article-title":"A Review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice","volume":"36","author":"Mueller","year":"2015","journal-title":"Subst. Abus."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-019-1048-y","article-title":"Naloxone interventions in opioid overdoses: a systematic review protocol","volume":"8","author":"Shaw","year":"2019","journal-title":"Syst. Rev."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0945","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/2042098617744161","article-title":"Naloxone dosage for opioid reversal: current evidence and clinical implications","volume":"9","author":"Rzasa Lynn","year":"2018","journal-title":"Therap. Adv. Drug Safety."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0950","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0885-3924(01)00369-4","article-title":"Low-dose oral naloxone reverses opioid-induced constipation and analgesia","volume":"23","author":"Liu","year":"2002","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0955","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0378-5173(86)90057-8","article-title":"Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides","volume":"33","author":"Aungst","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0960","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-5173(01)00634-2","article-title":"Transdermal delivery of naloxone: effect of water, propylene glycol, ethanol and their binary combinations on permeation through rat skin","volume":"219","author":"Panchagnula","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0965","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2011.10.042","article-title":"In vitro and in vivo transdermal iontophoretic delivery of naloxone, an opioid antagonist","volume":"422","author":"Yamamoto","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0970","doi-asserted-by":"crossref","unstructured":"S.A. Burton, C.-Y. Ng, R. Simmers, C. Moeckly, D. Brandwein, T. Gilbert, N. Johnson, K. Brown, T. Alston, G. Prochnow, K. Siebenaler, K. Hansen, Rapid Intradermal Delivery of Liquid Formulations Using a Hollow Microstructured Array, (n.d.). doi:https:\/\/doi.org\/10.1007\/s11095-010-0177-8.","DOI":"10.1007\/s11095-010-0177-8"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0975","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s13346-016-0332-9","article-title":"Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery","volume":"6","author":"Thakur","year":"2016","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0980","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2021.01.005","article-title":"In vivo safety assessment, biodistribution and toxicology of polyvinyl alcohol microneedles with 160-day uninterruptedly applications in mice","volume":"160","author":"Zhang","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0985","series-title":"Role of Polyvinylpyrrolidone in Dissolving Microneedle for Efficient Transdermal Drug Delivery: In vitro and Clinical Studies","author":"Shim","year":"2018"},{"key":"10.1016\/j.jconrel.2022.06.034_bb0990","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10717541003667798","article-title":"Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety","volume":"17","author":"Donnelly","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.06.034_bb0995","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.biomaterials.2007.12.048","article-title":"Dissolving microneedles for transdermal drug delivery","volume":"29","author":"Lee","year":"2008","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1000","doi-asserted-by":"crossref","first-page":"30575","DOI":"10.1021\/acsami.9b09697","article-title":"Biodegradable therapeutic microneedle patch for rapid antihypertensive treatment","volume":"11","author":"Li","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1005","series-title":"Evaluation of a Transdermal Buprenorphine Formulation In Opioid Detoxification","author":"Lanier","year":"2007"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13722-021-00244-8","article-title":"Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review","volume":"16","author":"Adams","year":"2021","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajp.2019.02.002","article-title":"Transdermal buprenorphine patch: potential for role in management of opioid dependence","volume":"40","author":"Dharwan","year":"2019","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1020","unstructured":"Transdermal System, Butrans\u00ae (buprenorphine) CIII, (n.d.). https:\/\/butrans.com\/delivery\/transdermal-patch.html (accessed March 30, 2022)."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/HRP.0000000000000079","article-title":"Pharmacotherapy for alcohol use disorder: current and emerging therapies","volume":"23","author":"Swift","year":"2015","journal-title":"Harvard Rev. Psychiatry."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1030","first-page":"653","article-title":"pharmacotherapy for alcohol use disorder","volume":"102","author":"Holt","year":"2018","journal-title":"Med. Clin."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1749-6632.2010.05900.x","article-title":"Intramuscular extended-release naltrexone: current evidence","volume":"1216","author":"Gastfriend","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: a half of a century later","volume":"26","author":"Suh","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1045","first-page":"4972","article-title":"Formulation and evaluation of acamprosate calcium implant using poly (Lactic-co-glycolic acid)","volume":"7","author":"Patil","year":"2016","journal-title":"Int. J. Pharm. Life Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1050","series-title":"Frontiers in Bioengineering and Biotechnology","article-title":"Viscoprene drug delivery system for the sustained release of disulfiram for treatment of alcohol use disorder","author":"Taylor","year":"2016"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1055","series-title":"Opiate Receptors and Antagonists: From Bench to Clinic","first-page":"655","article-title":"Nonclinical pharmacology of VIVITROL\u00ae: a monthly injectable naltrexone for the treatment of alcohol dependence","author":"Dean","year":"2009"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1060","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1755-5949.2010.00194.x","article-title":"Naltrexone depot formulations for opioid and alcohol dependence: a systematic review","volume":"17","author":"Lobmaier","year":"2011","journal-title":"CNS Neurosci. Therap."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/scipharm87030020","article-title":"Microparticles, microspheres, and microcapsules for advanced drug delivery","volume":"87","author":"Lengyel","year":"2019","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.04.013","article-title":"Polymer microspheres for controlled drug release","volume":"282","author":"Freiberg","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1075","doi-asserted-by":"crossref","unstructured":"M. Porras-Gomez, C. Leal, Lipid-Based Liquid Crystalline Films and Solutions for the Delivery of Cargo to Cells, (n.d.). doi:https:\/\/doi.org\/10.1080\/21680396.2019.1666752.","DOI":"10.1080\/21680396.2019.1666752"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/2231-4040.97286","article-title":"Effect of permeation enhancers on the penetration mechanism of transfersomal gel of ketoconazole","volume":"3","author":"Rajan","year":"2012","journal-title":"J. Adv. Pharmaceut. Technol. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1085","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1111\/add.15309","article-title":"Tobacco use disorder and the lungs","volume":"116","author":"McRobbie","year":"2021","journal-title":"Addiction."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1090","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/pharmaceutics7040438","article-title":"Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum","volume":"7","author":"Alkilani","year":"2015","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1095","first-page":"425","article-title":"Nicotine replacement therapy: an overview","volume":"10","author":"Wadgave","year":"2016","journal-title":"Int. J. Health Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1183\/09059180.00011004","article-title":"Pharmacological treatments for tobacco dependence","volume":"17","author":"Fagerstr\u00f6m","year":"2008","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1105","unstructured":"K.J. Holm, C.M. Spencer, N.L. Benowitz, J.E. Henningfield, P. Associates, D E Jorenby, M.A.H. Russell, Bupropion A Review of its Use in the Management of Smoking Cessation, n.d."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/1055049029008811","article-title":"Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care","volume":"11","author":"Gold","year":"2002","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1115","doi-asserted-by":"crossref","DOI":"10.3310\/hta6160","article-title":"The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation","volume":"6","author":"Woolacott","year":"2002","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1120","series-title":"A Controlled Trial of Sustained-Release Bupropion, a Nicotine Patch, or Both for Smoking Cessation","first-page":"161","volume":"7","author":"Jorenby","year":"2008"},{"issue":"2012","key":"10.1016\/j.jconrel.2022.06.034_bb1125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-200262002-00002","article-title":"Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation","volume":"62:2. 62","author":"Johnston","year":"2002","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.jconrel.2022.06.034_bb1130","first-page":"31","article-title":"Potential new drug delivery systems for antidepressants","volume":"64","author":"Kilts","year":"2003","journal-title":"An Overview"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1135","article-title":"Slow-sustained delivery of naloxone reduces typical naloxone-induced precipitated opioid withdrawal effects in male morphine-dependent mice","author":"L. LA, J. MC, T. AC, K. AJ, A. S, K. BJ","year":"2020","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1140","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3168\/jds.2010-3823","article-title":"Agar hydrogel with silver nanoparticles to prolong the shelf life of Fior di Latte cheese","volume":"94","author":"Incoronato","year":"2011","journal-title":"J. Dairy Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1145","series-title":"Agar: a natural and environmentally-friendly support composed of copper oxide nanoparticles for the green synthesis of 1,2,3-triazoles","author":"Maleki","year":"2019"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1150","first-page":"1","article-title":"Osmotic drug delivery system as a part of modified release dosage form","volume":"2012","author":"Keraliya","year":"2012","journal-title":"ISRN Pharma."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1155","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1007\/s11606-019-05074-8","article-title":"Pharmacotherapy for cocaine use disorder-a systematic review and meta-analysis","volume":"34","author":"Chan","year":"2019","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1160","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/nrn1539","article-title":"Drug addiction: the neurobiology of behavior gone awry","volume":"12","author":"Volkow","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1165","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.162.8.1432","article-title":"Medication development for addictive disorders: the state of the science","volume":"162","author":"Vocci","year":"2005","journal-title":"Am. J. Psychiatr."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2022.06.034_bb1170","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1360-0443.2007.01772.x","article-title":"Approaches to the development of medications for the treatment of methamphetamine dependence","volume":"102","author":"Vocci","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1175","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/add.13868","article-title":"PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial","volume":"112","author":"Schmitz","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/adb.12471","article-title":"PPAR\u03b3 agonism attenuates cocaine cue reactivity","volume":"23","author":"Miller","year":"2018","journal-title":"Addict. Biol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pbb.2017.07.002","article-title":"Atomoxetine in abstinent cocaine users: cognitive, subjective and cardiovascular effects","volume":"159","author":"DeVito","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/ADM.0b013e31826b767f","article-title":"Safety of atomoxetine in combination with intravenous cocaine in cocaine- experienced participants","volume":"6","author":"Cantilena","year":"2012","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jcph.789","article-title":"Pharmacokinetics and safety assessment of l-tetrahydropalmatine in cocaine users: a randomized, double-blind, placebo-controlled study","volume":"57","author":"Hassan","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.psychres.2006.03.012","article-title":"Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination","volume":"152","author":"Rotheram-Fuller","year":"2007","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1205","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.4088\/JCP.v64n1207","article-title":"Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use","volume":"64","author":"Shoptaw","year":"2003","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1210","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.drugalcdep.2012.11.021","article-title":"The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study","volume":"131","author":"Shorter","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030854","article-title":"Noradrenergic \u03b1\u2081 receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial","volume":"7","author":"Newton","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1220","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/sj.npp.1300999","article-title":"Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers","volume":"31:8. 31","author":"Haney","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1225","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drugalcdep.2010.11.023","article-title":"Oral administration of levo-tetrahydropalmatine attenuates reinstatement of extinguished cocaine seeking by cocaine, stress or drug-associated cues in rats","volume":"116","author":"Figueroa-Guzman","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1230","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.drugalcdep.2010.07.022","article-title":"Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients","volume":"113","author":"Oliveto","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.drugalcdep.2004.08.011","article-title":"Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing","volume":"77","author":"Marsch","year":"2005","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1240","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/archpsyc.61.3.264","article-title":"Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial","volume":"61","author":"Carroll","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1245","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1521-0391.2013.12032.x","article-title":"Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users","volume":"22","author":"Cunningham","year":"2013","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1250","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ijpharm.2017.06.041","article-title":"Effects of chemical and physical enhancement techniques on transdermal delivery of 3-fluoroamphetamine hydrochloride","volume":"528","author":"Puri","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1255","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1124\/jpet.108.143701","article-title":"Selective suppression of cocaine- Versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+) phenmetrazine, and 4-benzylpiperidine","volume":"329","author":"Negus","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1260","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2018.08.033","article-title":"Formulation and evaluation of 4-benzylpiperidine drug-in-adhesive matrix type transdermal patch","volume":"550","author":"Ganti","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1265","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2165\/00003495-199243060-00003","article-title":"Appetite suppressants. A review","volume":"43","author":"Silverstone","year":"1992","journal-title":"Drugs."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1270","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-019-0335-9","article-title":"Skin delivery and irritation potential of phenmetrazine as a candidate transdermal formulation for repurposed indications","volume":"21","author":"Jiang","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1275","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.5530\/ijper.50.3.27","article-title":"Pharmaceutical pellets: a versatile carrier for oral controlled delivery of drugs","volume":"50","author":"Yadav","year":"2016","journal-title":"Indian J. Pharm. Edu. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1280","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.4314\/tjpr.v7i3.14692","article-title":"Multiparticulate drug delivery systems for controlled release","volume":"7","author":"Dey","year":"2008","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1285","series-title":"Modified-Release Drug Products, in: Applied Biopharmaceutics & Pharmacokinetics","first-page":"469","author":"Shargel","year":"2012"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1290","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.drugalcdep.2008.08.009","article-title":"Cocaine effects during d-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy","volume":"99","author":"Rush","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"2003","key":"10.1016\/j.jconrel.2022.06.034_bb1295","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/sj.npp.1300392","article-title":"Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials","volume":"29:5. 29","author":"Grabowski","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1300","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/JCP.0000000000000789","article-title":"Late reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs perphenazine in schizophrenia and comorbid cocaine dependence","volume":"37","author":"Beresford","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1305","series-title":"Mixed amphetamine salts extended release: a clinical review of its use in the treatment of attention-deficit hyperactivity disorder","first-page":"525","volume":"1","author":"Grcevich","year":"2006"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1310","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.biopsych.2012.05.032","article-title":"Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial","volume":"72","author":"Mariani","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1315","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107700","article-title":"Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized clinical replication trial with frequent users","volume":"206","author":"Levin","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1330","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-007-0861-5","article-title":"Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users","volume":"194","author":"Huestis","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1335","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":"Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716","volume":"58","author":"Huestis","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1340","doi-asserted-by":"crossref","first-page":"P50","DOI":"10.1016\/j.clpt.2005.12.177","article-title":"PII-52Rimonabant pharmacokinetics in healthy and obese subjects","volume":"79","author":"Turpault","year":"2006","journal-title":"Clin. Pharmacol. Therap."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1345","first-page":"187","article-title":"N-Acetylcysteine (NAC) in young marijuana users: an open-label pilot study","volume":"19","author":"Gray","year":"2010","journal-title":"Am. J. Addi. Am. Acad. Psych. Alcohol. Addict."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1350","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00228","article-title":"Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review","volume":"10","author":"Ahmed","year":"2019","journal-title":"Front. Psychiatry."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1355","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/npp.2012.14","article-title":"A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults","volume":"37","author":"Mason","year":"2012","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1360","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/npp.2010.58","article-title":"Cannabidiol attenuates the appetitive effects of \u03949-tetrahydrocannabinol in humans smoking their chosen cannabis","volume":"35","author":"Morgan","year":"2010","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1365","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/can.2017.0043","article-title":"Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial","volume":"3","author":"Solowij","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1370","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jcpt.12018","article-title":"Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report","volume":"38","author":"Crippa","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1375","first-page":"865","article-title":"Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial, The Lancet","volume":"7","author":"Freeman","year":"2020","journal-title":"Psychiatry."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1380","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drugalcdep.2011.01.003","article-title":"Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal","volume":"117","author":"Vandrey","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1385","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.drugalcdep.2018.02.022","article-title":"The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration","volume":"187","author":"Schlienz","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1390","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jsat.2008.01.002","article-title":"Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse","volume":"35","author":"Budney","year":"2008","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1395","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.npp.1300310","article-title":"Marijuana withdrawal in humans: effects of oral THC or divalproex","volume":"29","author":"Haney","year":"2004","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1400","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0376-8716(02)00084-4","article-title":"Effects of oral THC maintenance on smoked marijuana self-administration","volume":"67","author":"Hart","year":"2002","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1405","first-page":"161","article-title":"Use of dronabinol for cannabis dependence: two case reports and review","volume":"17","author":"Levin","year":"2008","journal-title":"Am. J. Addi. Am. Acad. Psych. Alcohol. Addict."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1410","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/npp.2015.108","article-title":"Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers","volume":"40","author":"Haney","year":"2015","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1415","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jsps.2021.07.015","article-title":"Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies","volume":"29","author":"Elmowafy","year":"2021","journal-title":"Saudi Pharmaceut. J."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1465","author":"WO2021011529"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1495","author":"WO2019113470"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1500","author":"Akiyoshi"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1580","unstructured":"US-11000479-B2 - Injectable Long-acting Naltrexone Microparticle Compositions | Unified Patents, (n.d.). https:\/\/portal.unifiedpatents.com\/patents\/patent\/US-11000479-B2 (accessed March 18, 2022)."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1625","unstructured":"Opioid Compositions Resistant to Overdose and Abuse - Elysium Therapeutics, Inc., (n.d.). https:\/\/www.freepatentsonline.com\/y2020\/0093817.html (accessed March 19, 2022)."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1665","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jppr.1477","article-title":"Sustained-release subdermal buprenorphine implants: the future of opioid use disorder management?","volume":"49","author":"Shephard","year":"2019","journal-title":"J. Pharm. Pract. Res."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1670","doi-asserted-by":"crossref","first-page":"e219708","DOI":"10.1001\/jamanetworkopen.2021.9708","article-title":"Extended-release buprenorphine and its evaluation with patient-reported outcomes","volume":"4","author":"Compton","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1675","first-page":"1","article-title":"Controlled drug delivery vehicles for cancer treatment and their performance","volume":"3","author":"Senapati","year":"2018","journal-title":"Signal Trans. Target. Therapy."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1680","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.xphs.2017.11.013","article-title":"Dissolving microneedles loaded with etonogestrel microcrystal particles for intradermal sustained delivery","volume":"107","author":"He","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1685","doi-asserted-by":"crossref","unstructured":"M.I. Nasiri, L.K. Vora, Juhaina, A. Ershaid, Ke Peng, I.A. Tekko, R.F. Donnelly, Nanoemulsion-Based Dissolving Microneedle arrays for Enhanced Intradermal and Transdermal Delivery, (n.d.). doi:10.1007\/s13346-021-01107-0.","DOI":"10.1007\/s13346-021-01107-0"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1690","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.jconrel.2022.06.034_bb1695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0376-8716(85)90076-6","article-title":"Clinical evaluation of a naltrexone sustained-release preparation","volume":"16","author":"Chiang","year":"1985","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jconrel.2022.06.034_bb1700","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0190-9622(85)70135-1","article-title":"Cutaneous reactions secondary to heparin injections","volume":"12","author":"Tuneu","year":"1985","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922003753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922003753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:40:38Z","timestamp":1759164038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922003753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":265,"alternative-id":["S0168365922003753"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.06.034","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained drug delivery strategies for treatment of common substance use disorders: Promises and challenges","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}